MDACC Study No:2010-0509 ( NCT No: NCT01211691)
Title:Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3-Expressing Hematologic Malignancies
Principal Investigator:Jorge Cortes
Treatment Agent:KB004
Study Status:Closed
Study Description:The goal of Part 1 (Dose Escalation) of this clinical research study was to
find the highest tolerable dose of KB004 that can be given safely to patients
with leukemia or another type of blood cancer. No more participants will be
enrolled on Part 1 at MD Anderson.

The goal of Part 2 (Cohort Expansion) of the study is to further study the
activity of KB004 in people with the same blood cancer and whose cancers
express EphA3. The safety of KB004 will also be studied. All new participants
at MD Anderson will be enrolled in Part 2 of the study.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:N/A
Treatment Agents:KB004
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:KaloBios Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults